Researchers at Leiden University Medical Center (LUMC), in collaboration with Erasmus MC and the Oncode Institute, have developed a novel vaccine targeting non-small cell lung cancer (NSCLC). This vaccine aims to expose cancer cells that have evaded the immune system, potentially enhancing the effectiveness of immunotherapy treatments.
In a preliminary clinical study involving 26 patients with advanced NSCLC, the vaccine demonstrated safety and elicited an immune response in over 80% of participants. The vaccine works by training immune cells to recognize a specific protein, TEIPP, present only on cancer cells that have become invisible to the immune system. By making these hidden cells detectable again, the immune system can more effectively target and destroy them.
While these initial results are promising, further research is needed to determine the vaccine’s impact on tumor reduction and patient survival. Future studies will explore optimal dosing schedules and the potential benefits of combining the vaccine with existing immunotherapies.
This approach highlights the collaborative efforts within the Leiden Bio Science Park to advance cancer treatment through innovative research.
Read more here: https://www.lumc.nl/actueel/2025/vaccin-tegen-longkanker/
We recently hosted Tjerk Opmeer from the Ministry of Economic Affairs at Leiden Bio Science Park to share insights into building a shared investment agenda for Dutch biotech....
A new collaboration between TNO, Proefdiervrij, and pharmaceutical company Galapagos, called MechPath, is accelerating the transition to animal-free drug development. By...
The first Works Council Community meeting at Leiden Bio Science Park tackled workplace conduct and culture through honest, practical dialogue. With HR and legal experts in the room, the session marked the start of a collaborative effort to foster safer, more respectful workplaces.